Literature DB >> 15603851

Tenascin-C, over expressed in lung cancer down regulates effector functions of tumor infiltrating lymphocytes.

Kalpaj Parekh1, Sabarinathan Ramachandran, Joel Cooper, Darell Bigner, Alexander Patterson, T Mohanakumar.   

Abstract

PURPOSE: Extracellular matrix (ECM) proteins play a significant role in the survival and metastasis of cancer cells. Tenascin-C (TN-C) is an extracellular matrix protein and its large isoform has been implicated in tumor progression. Goal of this study was to analyze the expression of the small and large isoforms of TN-C in non-small cell lung cancer (NSCLC) and determine its functional significance. EXPERIMENTAL
DESIGN: TN-C expression was studied in tumor and non-tumor tissue of patients with NSCLC at the mRNA and protein level. Immunomodulatory properties of the large isoform of TN-C were analyzed by determining its effect on lymphocyte proliferation and cytokine secretion by tumor-infiltrating lymphocytes (TIL).
RESULTS: Quantitative real-time PCR analysis showed an eight-fold increase in the amount of large isoform in cancer cells compared to adjacent normal tissue. Expression at the protein level by Western blot analysis using a murine monoclonal anti-TN-C antibody detected increased expression of the large isoform in the tumor tissue that was correlated with the development of recurrent disease. A 18-fold increase in the expression of the large TN-C isoform was observed in patients with recurrent NSCLC compared to non-recurrent NSCLC. Large isoform of TN-C significantly inhibited anti-CD3 and mitogen-induced proliferation of human peripheral blood lymphocytes and interferon-gamma production by TIL isolated from the lung cancer specimens.
CONCLUSIONS: Increased expression of TN-C observed at the site of tumor in NSCLC correlates with recurrence. TN-C inhibits TIL proliferation and cytokine thereby may promote tumor immune evasion and recurrence.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15603851     DOI: 10.1016/j.lungcan.2004.05.016

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  24 in total

1.  Differentiation-dependent differences in murine T cell susceptibility to negative regulation by the lung.

Authors:  Rhea Y Busick; Rama D Yammani; Martha A Alexander-Miller
Journal:  Am J Respir Cell Mol Biol       Date:  2011-01-07       Impact factor: 6.914

2.  Mechanisms of malignant glioma immune resistance and sources of immunosuppression.

Authors:  German G Gomez; Carol A Kruse
Journal:  Gene Ther Mol Biol       Date:  2006

3.  Clinical significance of serum tenascin-c levels in epithelial ovarian cancer.

Authors:  Tastekin Didem; Tas Faruk; Karabulut Senem; Duranyildiz Derya; Serilmez Murat; Guveli Murat; Kaynur Oznur
Journal:  Tumour Biol       Date:  2014-04-11

Review 4.  Positive and negative influence of the matrix architecture on antitumor immune surveillance.

Authors:  Elisa Peranzoni; Ana Rivas-Caicedo; Houcine Bougherara; Hélène Salmon; Emmanuel Donnadieu
Journal:  Cell Mol Life Sci       Date:  2013-05-07       Impact factor: 9.261

5.  Matricellular proteins: a sticky affair with cancers.

Authors:  Han Chung Chong; Chek Kun Tan; Royston-Luke Huang; Nguan Soon Tan
Journal:  J Oncol       Date:  2012-02-09       Impact factor: 4.375

6.  Cellular cancer vaccines: an update on the development of vaccines generated from cell surface antigens.

Authors:  Petr G Lokhov; Elena E Balashova
Journal:  J Cancer       Date:  2010-11-29       Impact factor: 4.207

7.  Selection of suitable reference genes for accurate normalization of gene expression profile studies in non-small cell lung cancer.

Authors:  Silvia Saviozzi; Francesca Cordero; Marco Lo Iacono; Silvia Novello; Giorgio V Scagliotti; Raffaele A Calogero
Journal:  BMC Cancer       Date:  2006-07-26       Impact factor: 4.430

8.  The role of tenascin-C in tissue injury and tumorigenesis.

Authors:  Kim S Midwood; Gertraud Orend
Journal:  J Cell Commun Signal       Date:  2009-10-17       Impact factor: 5.782

Review 9.  Nanoparticle-Based Therapies for Turning Cold Tumors Hot: How to Treat an Immunosuppressive Tumor Microenvironment.

Authors:  Giulio Giustarini; Andrea Pavesi; Giulia Adriani
Journal:  Front Bioeng Biotechnol       Date:  2021-06-02

10.  Immune Remodeling of the Extracellular Matrix Drives Loss of Cancer Stem Cells and Tumor Rejection.

Authors:  Ana Pires; Alexander Greenshields-Watson; Emma Jones; Andrew Godkin; Awen Gallimore; Kathryn Smart; Sarah N Lauder; Michelle Somerville; Stefan Milutinovic; Howard Kendrick; James P Hindley; Rhiannon French; Matthew J Smalley; William J Watkins; Robert Andrews
Journal:  Cancer Immunol Res       Date:  2020-10-06       Impact factor: 12.020

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.